Kinetic Spectrophotometric Determination of Gemifloxacin Mesylate and Moxifloxacin Hydrochloride in Pharmaceutical Preparations Using 4-Chloro-7-nitrobenzo-2-oxa-1,3-diazole

Table 7

Interday and intraday accuracy and precision for the determination of GMF and MOX in bulk powders by the proposed method (fixed time).

Drug	Taken 𝜇g mL^−1	Found 𝜇g mL^−1	RSD%^a	RE%^a	Recovery%^b ± SD
Interday
GMF	1.0	1.002	0.37	0.20	100.20±0.37
	3.0	2.99	0.25	−0.33	99.67±0.25
	5.0	4.96	0.31	−0.80	99.20±0.31
	7.0	7.04	0.52	0.57	100.57±0.52
Mean ± SD					99.91±0.60
MOX	3.0	2.98	0.23	−0.67	99.33±0.23
	6.0	6.02	0.40	0.33	100.33±0.40
	9.0	8.98	0.42	−0.22	99.78±0.42
	12	11.97	0.39	−0.25	99.75±0.39
Mean ± SD					99.80±0.41
Intraday
GMF	1.0	0.997	0.18	−0.30	99.70±0.18
	3.0	2.97	0.11	−1.0	99.00±0.11
	5.0	4.98	0.27	−0.40	99.60±0.27
	7.0	6.96	0.30	−0.57	99.43±0.30
Mean ± SD					99.43±0.31
MOX	3.0	3.04	0.21	1.33	101.33±0.21
	6.0	5.95	0.35	−0.83	99.17±0.35
	9.0	9.04	0.29	0.44	100.44±0.29
	12	12.07	0.27	0.58	100.58±0.27
Mean ± SD					100.38±0.90

aRSD%: percentage relative standard deviation; RE%: percentage relative error.
bAverage of six determinations.